Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders Equity
CONSOLIDATED STATEMENTS OFCHANGES IN SHAREHOLDERS’ EQUITY
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Other · Total | ||||||
| Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2021 | 169,477 | $434,529 | $(337,097) | $(1,323) | $(5,211) | $90,898 |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 20 | (17) | — | — | — | (17) |
| Stock-based compensation | — | 4,287 | — | — | — | 4,287 |
| Shares issued upon exercise of stock options | 596 | 490 | — | — | — | 490 |
| Subsidiary warrant exercise, net | — | 991 | — | — | — | 991 |
| Unrealized loss on marketable debt securities | — | — | — | — | (150) | (150) |
| Foreign currency translation gain | — | — | — | — | 1,790 | 1,790 |
| NET LOSS | — | — | (26,273) | (80) | — | (26,353) |
| BALANCE - December 31, 2022 | 170,093 | 440,280 | (363,370) | (1,403) | (3,571) | 71,936 |
| Shares issued through ATM | 4,775 | 6,625 | — | — | — | 6,625 |
| Financing related fees | — | (221) | — | — | — | (221) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 53 | (37) | — | — | — | (37) |
| Shares issued upon exercise of stock options | 66 | 56 | — | — | — | 56 |
| Stock-based compensation | — | 4,640 | — | — | — | 4,640 |
| Unrealized gain on marketable debt securities | — | — | — | — | 150 | 150 |
| Foreign currency translation gain | — | — | — | — | 353 | 353 |
| NET LOSS | — | — | (21,486) | 7 | — | (21,479) |
| BALANCE - December 31, 2023 | 174,987 | $451,343 | $(384,856) | $(1,396) | $(3,068) | $62,023 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.